Advertisement
Review Article| Volume 11, SUPPLEMENT 2, S3-S9, December 2007

Human papillomavirus infection and the development of cervical cancer and related genital neoplasias

  • Jorma Paavonen
    Correspondence
    Address correspondence to: Jorma Paavonen, MD, Department of Obstetrics and Gynecology, University of Helsinki, University Hospital, Haartmaninkatu 2, Helsinki, Finland 00029. Tel.: +358-9- 4717-2807; Fax: +358-9-4717-4902
    Affiliations
    Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
    Search for articles by this author
Open ArchiveDOI:https://doi.org/10.1016/S1201-9712(07)60015-0
Human papillomavirus infection and the development of cervical cancer and related genital neoplasias
Previous ArticleVaccines at the turn of the 21st century: a new era for immunization in public health
Next ArticleCorrelating immunity with protection for HPV infection
      This paper is only available as a PDF. To read, Please Download here.

      Summary

      Background

      The human papillomaviruses (HPV) are simple, nonenveloped, double-stranded DNA viruses, which are responsible for an enormous global burden of genital disease. HPV is associated with 500,000 new cases of cervical cancer and 250,000 cervical cancer deaths worldwide each year. Oncogenic HPV types 16 and 18 are responsible for a majority of cervical cancers and can also cause low- and high-grade cervical lesions (CIN 1, 2, 3) as well as high-grade vulvar or vaginal intraepithelial neoplasia (VIN or VaIN 2/3). Nononcogenic types HPV 6 and 11 also contribute to the overall burden of HPV disease, giving rise to CIN 1, anogenital warts, cutaneous lesions, and respiratory papillomatosis.

      Perspectives

      A substantial body of clinical evidence demonstrates the effectiveness of cytological screening in preventing cervical cancer, but these techniques have not eradicated the disease and are not widely available in most developing countries. Furthermore, evaluation and management of HPV-associated cytologic abnormalities is costly, drains health care resources, and increases the risk for adverse pregnancy outcome.

      Conclusions

      Targeting cervical cancer through universal immunization with a quadrivalent HPV 6, 11, 16, 18 vaccine may herald the beginning of the end of this deadly disease and substantially reduce the overall global burden of HPV-related genital diseases.

      Key words

      References

        • Department of Health and Human Services Centers for Disease Control and Prevention
        Genital HPV Infection Fact Sheet (web site).
        http://www.cdc.gov/std/hpv/stdfact-hpv.htm
        Date: 2004
        (accessed 2/26/06.)
        • World Health Organization
        Initiative for vaccine research.
        Human papillomavirus. World Health Organization, Geneva, Switzerland2006
        http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html
        (accessed 6/29/06.)
        • Bosch FX
        • Manos MM
        • Munoz N
        • Sherman M
        • Jansen AM
        • Peto J
        • et al.
        Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.
        J Natl Cancer Inst. 1995; 87: 796-802
        • Walboomers JM
        • Jacobs MV
        • Manos MM
        • Bosch FX
        • Kummer JA
        • Shah KV
        • et al.
        Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
        J Pathol. 1999; 189: 12-19
        • Basta A
        • Adamek K
        • Pitynski K
        Intraepithelial neoplasia and early stage vulvar cancer. Epidemiological, clinical and virological observations.
        Eur J Gynaecol Oncol. 1999; 20: 111-114
        • Daling JR
        • Madeleine MM
        • Johnson LG
        • Schwartz SM
        • Shera KA
        • Wurscher MA
        • et al.
        Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease.
        Int J Cancer. 2005; 116: 606-616
        • Daling JR
        • Madeleine MM
        • Schwartz SM
        • Shera KA
        • Carter JJ
        • McKnight B
        • et al.
        A population-based study of squamous cell vaginal cancer: HPV and cofactors.
        Gynecol Oncol. 2002; 84: 263-270
        • Moscicki AB
        • Hills N
        • Shiboski S
        • Powell K
        • Jay N
        • Hanson E
        • et al.
        Risks for incident human papillomavirus infection and lowgrade squamous intraepithelial lesion development in young females.
        JAMA. 2001; 285: 2995-3002

      9. World Health Organization, Department of Vaccines and Other Biologicals and International Agency for Research on Cancer. The current status of development of prophylactic vaccines against human papillomavirus infection: report of a technical meeting, 16–18 February, 1999, Geneva, Switzerland. 1999. Geneva, Switzerland, World Health Organization.

        • Hatch KD
        • Berek JS
        Intraepithelial diseases of the cervix, vagina, and vulva.
        in: Berek JS Novak's Gynecology. Lippincott Williams & Wilkins, Philadelphia2002: 471-505
        • Minucci D
        • Cinel A
        • Insacco E
        • Oselladore M
        Epidemiological aspects of vaginal intraepithelial neoplasia (VAIN).
        Clin Exp Obstet Gynecol. 1995; 22: 36-42
        • Maw RD
        • Reitano M
        • Roy M
        An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle.
        Int J STD AIDS. 1998; 9: 571-578
        • Abramson AL
        • Nouri M
        • Mullooly V
        • Fisch G
        • Steinberg BM
        Latent Human Papillomavirus infection is comparable in the larynx and trachea.
        J Med Virol. 2004; 72: 473-477
        • Derkay CS
        • Darrow DH
        Recurrent respiratory papillomatosis.
        Ann Otol Rhinol Laryngol. 2006; 115: 1-11
        • Moscicki AB
        Impact of HPV infectioninadolescentpopulations.
        J Adolesc Health. 2005; 37: S3-S9
        • Centers for Disease Control and Prevention
        National Center for HIV, STD and TB Prevention Division of Sexually Transmitted Diseases. STD prevention: Genital HPV infection [fact sheet]. 2006. Centers for Disease Control and Prevention.
        http://www.cdc.gov/std/hpv/stdfact-hpv.htmhttp://www.cdc.gov/std/hpv/stdfact-hpv.htm
        (accessed 6/29/06.)
        • zur Hausen H
        Papillomavirus infections – a major cause of human cancers.
        Biochim Biophys Acta. 1996; 1288: F55-F78
        • de Villiers EM
        • Fauquet C
        • Broker TR
        • Bernard HU
        • zur Hausen H
        Classification of papillomaviruses.
        Virology. 2004; 324: 17-27
        • Berzofsky JA
        • Ahlers JD
        • Janik J
        • Morris J
        • Oh S
        • Terabe M
        • et al.
        Progress on new vaccine strategies against chronic viral infections.
        J Clin Invest. 2004; 114: 450-462
        • Parkin DM
        • Bray F
        Chapter 2: The burden of HPV-related cancers.
        Vaccine. 2006; 24: S11-S25
        • Munoz N
        • Bosch FX
        • de Sanjose S
        • Herrero R
        • Castellsague X
        • Shah KV
        • et al.
        Epidemiologic classification of human papillomavirus types associated with cervical cancer.
        N Engl J Med. 2003; 348: 518-527
        • Clifford GM
        • Gallus S
        • Herrero R
        • Munoz N
        • Snijders PJ
        • Vaccarella S
        • et al.
        Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.
        Lancet. 2005; 366: 991-998
        • Munoz N
        • Bosch FX
        • Castellsague X
        • Diaz M
        • de Sanjose S
        • Hammouda D
        • et al.
        Against which human papillomavirus types shall we vaccinate and screen? The international perspective.
        Int J Cancer. 2004; 111: 278-285
        • Clifford GM
        • Rana RK
        • Franceschi S
        • Smith JS
        • Gough G
        • Pimenta JM
        Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 1157-1164
        • Clifford GM
        • Smith JS
        • Aguado T
        • Franceschi S
        Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis.
        Br J Cancer. 2003; 89: 101-105
        • Bauer HM
        • Ting Y
        • Greer CE
        • Chambers JC
        • Tashiro CJ
        • Chimera J
        • et al.
        Genital human papillomavirus infection in female university students as determined by a PCR-based method.
        JAMA. 1991; 265: 472-477
        • Ho GY
        • Bierman R
        • Beardsley L
        • Chang CJ
        • Burk RD
        Natural history of cervicovaginal papillomavirus infection in young women.
        N Engl J Med. 1998; 338: 423-428
        • Stone KM
        • Karem KL
        • Sternberg MR
        • McQuillan GM
        • Poon AD
        • Unger ER
        • et al.
        Seroprevalence of human papillomavirus type 16 infection in the United States.
        J Infect Dis. 2002; 186: 1396-1402
        • Collins S
        • Mazloomzadeh S
        • Winter H
        • Blomfield P
        • Bailey A
        • Young LS
        • et al.
        High incidence of cervical human papillomavirus infection in women during their first sexual relationship.
        BJOG. 2002; 109: 96-98
        • Bosch FX
        • de Sanjose S
        Chapter 1: Human papillomavirus and cervical cancer – burden and assessment of causality.
        J Natl Cancer Inst Monogr. 2003; : 3-13
        • Auvinen E
        • Niemi M
        • Malm C
        • Zilliacus R
        • Trontti A
        • Fingerroos R
        • et al.
        High prevalence of HPV among female students in Finland.
        Scand J Infect Dis. 2005; 37: 873-876
        • Winer RL
        • Lee SK
        • Hughes JP
        • Adam DE
        • Kiviat NB
        • Koutsky LA
        Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.
        Am J Epidemiol. 2003; 157: 218-226
        • Munoz N
        • Mendez F
        • Posso H
        • Molano M
        • van den Brule AJ
        • Ronderos M
        • et al.
        Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results.
        J Infect Dis. 2004; 190: 2077-2087
        • Richardson H
        • Kelsall G
        • Tellier P
        • Voyer H
        • Abrahamowicz M
        • Ferenczy A
        • et al.
        The natural history of type-specific human papillomavirus infections in female university students.
        Cancer Epidemiol Biomarkers Prev. 2003; 12: 485-490
        • Brown DR
        • Shew ML
        • Qadari B
        • Neptune N
        • Vargas M
        • Tu W
        • et al.
        A longitudinal study of genital papillomavirus infection in a cohort of closely followed adolescent women.
        J Infect Dis. 2006; 191: 182-192
        • World Health Organization
        Comprehensive cervical cancer control: a guide to essential practice.
        http://www.who.int/reproductive-health/publications/cervical_cancer_gep/index.htm
        (accessed 6/24/06. 2006. Geneva, Switzerland, World Health Organization.)
        • Ferlay J.
        • Bray F.
        • Pisani P.
        • Parkin D.M.
        GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, version 2.0. 2004. IARC CancerBase No. 5. IARC Press, Lyon, France2004
        • American Cancer Society
        Cancer Facts & Figures. American Cancer Society, Atlanta, Ga2005: 1-60
        • American Cancer Society
        Cancer Reference Information.
        Available at: http://www.cancer.org
        Date: 2006
        (Accessed March 30, 2006.)
        • Herrero R
        • Castellsague X
        • Pawlita M
        • Lissowska J
        • Kee F
        • Balaram P
        • et al.
        Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.
        J Natl Cancer Inst. 2003; 95: 1772-1783
        • Joura EA
        Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia.
        Curr Opin Obstet Gynecol. 2002; 14: 39-43
        • Sturgeon SR
        • Brinton LA
        • Devesa SS
        • Kurman RJ
        In situ and invasive vulvar cancer incidence trends (1973 to 1987).
        Am J Obstet. Gynecol. 1992; 166: 1482-1485
        • Buscema J
        • Naghashfar Z
        • Sawada E
        • Daniel R
        • Woodruff JD
        • Shah K
        The predominance of human papillomavirus type 16 in vulvar neoplasia.
        Obstet Gynecol. 1988; 71: 601-606
        • Koutsky L
        Epidemiology of genital human papillomavirus infection.
        Am J Med. 1997; 102: 3-8
        • Burd EM
        Human papillomavirus and cervical cancer.
        Clin Microbiol Rev. 2003; 16: 1-17
        • Lacey CJ
        • Lowndes CM
        • Shah KV
        Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.
        Vaccine. 2006; 24: S35-S41
        • Winer RL
        • Kiviat NB
        • Hughes JP
        • Adam DE
        • Lee SK
        • Kuypers JM
        • et al.
        Development and duration of human papillomavirus lesions, after initial infection.
        J Infect Dis. 2005; 191: 731-738
        • Wiley DJ
        • Douglas J
        • Beutner K
        • Cox T
        • Fife K
        • Moscicki AB
        • et al.
        External genital warts: diagnosis, treatment, and prevention.
        Clin Infect Dis. 2002; 35: S210-S224
        • Soper DE
        Genitourinary infections and sexually transmitted diseases.
        in: Berek JS Novak's Gynecology. Lippincott Williams & Wilkins, Philadelphia2002: 453-470
        • Persson G
        • Dahlof LG
        • Krantz I
        Physical and psychological effects of anogenital warts on female patients.
        Sex Transm Dis. 1993; 20: 10-13
        • Chandler MG
        Genital warts: a study of patient anxiety and information needs.
        Br J Nurs. 1996; 5: 174-179
        • Taylor CA
        • Keller ML
        • Egan JJ
        Advice from affected persons about living with human papillomavirus infection.
        Image J Nurs Sch. 1997; 29: 27-32
        • von Krogh G
        Management of anogenital warts (condylomata acuminata).
        Eur J Dermatol. 2001; 11: 598-603
        • Bray F
        • Loos AH
        • McCarron P
        • Weiderpass E
        • Arbyn M
        • Moller H
        • et al.
        Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 677-686
        • Trottier H
        • Franco EL
        The epidemiology of genital human papillomavirus infection.
        Vaccine. 2006; 24: S1-S15

      56. Planning and implementing cervical cancer prevention and control programs. A manual for managers. 1–279. 2004. Seattle, Washington, Alliance for Cervical Cancer Prevention.

        • Soper D
        Reducing the health burden of HPV through vaccination.
        Infect Dis Obstet Gynecol. 2006; (Article ID 83084): 1-5
        • Kalliala I
        • Anttila A
        • Pukkala E
        • Nieminen P
        Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study.
        BMJ. 2005; 331: 1183-1185
        • Kyrgiou M
        • Koliopoulos G
        • Martin-Hirsch P
        • Arbyn M
        • Prendiville W
        • Paraskevaidis E
        Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis.
        Lancet. 2006; 367: 489-498
        • Frazer IH
        Prevention of cervical cancer through papillomavirus vaccination.
        Nat Rev Immunol. 2004; 4: 46-54
        • Anttila A
        • Ronco G
        • Clifford G
        • Bray F
        • Hakama M
        • Arbyn M
        • et al.
        Cervical cancer screening programmes and policies in 18 European countries.
        Br J Cancer. 2004; 91: 935-941
        • van Ballegooijen M
        • van den Akker-van Marle
        • Patnick J
        • Lynge E
        • Arbyn M
        • Anttila A
        • et al.
        Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness.
        Eur J Cancer. 2000; 36: 2177-2188
        • US Department of Health and Human Services
        2nd edition. Healthy People 2010. Vol 1–2. US Government Printing Office, Washington DC2000 (Level III) 2000.
      64. Clinical Management Guidelines for Obstetrician-Gynecologists.
        ACOG Practice Bulletin. 2003; 102: 417-427

      65. Clinical US Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2002.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S1201-9712(07)60015-0

      Copyright

      © 2007 International Society of Infectious Diseases. Published by Elsevier Inc.

      User license

      Elsevier user license |
      How you can reuse Information Icon
      Elsevier user license

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Text & data mine
      • Translate the article

      Not Permitted

      • Reuse portions or extracts from the article in other works
      • Redistribute or republish the final article
      • Sell or re-use for commercial purposes

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX